Evidence map›Paper›PMID 38492066›Full record

ArticleInternational journal of clinical oncology2024

Salivary gland-type cancers: cross-organ demographics of a rare cancer.

Aika Tanzawa, Kengo Saito, Masayuki Ota, Koji Takahashi, Izumi Ohno, Toyoyuki Hanazawa, Katsuhiro Uzawa, Yuichi Takiguchi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Are HPV oncogenic viruses involved in salivary glands tumorigenesis?Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Aika TanzawaDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Kengo SaitoDepartment of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masayuki OtaDepartment of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Koji TakahashiDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Izumi OhnoDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Toyoyuki HanazawaDepartment of Otorhinolaryngology/Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Katsuhiro UzawaDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuichi TakiguchiDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. takiguchi@faculty.chiba-u.jp.ORCID http://orcid.org/0000-0001-6059-7476
Chiba University · JP

Funding

the Ministry of Education, Culture, Sports, Science and Technology in Japan Kiban-C #20K08561the Ministry of Education, Culture, Sports, Science and Technology in Japan the Kanto Academic Alliance for Fostering Cancer Professionals
6 · The paper itself

Abstract

backgroundSalivary gland-type cancers (SGTCs) are histologically heterogeneous and can affect organs other than the salivary glands. Some tumors outside the salivary glands are diagnosed on their unique histological characteristics. Comprehensive cross-organ studies on SGTCs are limited.

methodsWe retrospectively analyzed the data of patients with salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), acinic cell carcinoma (AcCC), and polymorphous adenocarcinoma (PAC) who visited our institution between 2009 and 2019. The primary tumor sites were classified into four categories; major salivary glands, head/neck (H/N) excluding (exc) major salivary glands (MSG) regions, broncho-pulmonary regions, and "others". H/N exc MSG was further divided into three subcategories, nasal/paranasal sinus, oral and pharynx/larynx.

resultsWe identified 173 patients with SGTCs, with SDC, AdCC, MEC, EMC, AcCC, and PAC accounting for 20%, 42%, 27%, 3%, 8%, and 1% of the cases, respectively. The most frequent primary site was the major salivary glands (64%), followed by H/N exc MSG regions (27%), broncho-pulmonary regions, and "others", thus non-salivary gland origins accounted for 9% of all cases. Patients with SDC, MEC, AcCC, or SGTC of the major salivary glands and broncho-pulmonary regions were more frequently treated by surgery. The overall survival time of the patients with MEC was significantly better than that of patients with SDC or EMC.

conclusionsThis cross-organ study highlights the clinical significance of SGTCs, underscoring the need for developing novel therapies for this rare disease entity.

Indexed as

Carcinoma, Adenoid CysticCarcinoma, MucoepidermoidSalivary Gland NeoplasmsAdenocarcinomaAdolescentAdultAgedAged, 80 and overCarcinoma, Acinar CellFemaleHumansMaleMiddle AgedRetrospective StudiesSalivary GlandsYoung AdultAcinic cell carcinomaAdenoid cystic carcinomaBroncho-pulmonaryCross-organEpithelial-myoepithelial carcinomaMucoepidermoid carcinoma

Identifiers

PMID38492066
PMCPMC11130055
OpenAlexW4392882251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.